Federal Circuit Affirms Invalidity of Cardiovalve Heart Valve Patent
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Cardiovalve, Ltd. v. Edwards Lifesciences, Co. |
| Case Number | 22-2230 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | Sep 2022 – Mar 2024 1 year 6 months |
| Outcome | Defendant Win — Unpatentability Affirmed |
| Patent at Issue | |
| Accused Products | Edwards’ Heart Valve Implant Products |
Case Overview
In a significant decision for medical device patent litigation, the U.S. Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board’s (PTAB) ruling that the patent asserted by Cardiovalve, Ltd. was unpatentable. Case No. 22-2230, Cardiovalve, Ltd. v. Edwards Lifesciences, Co., closed on March 21, 2024, after 547 days of appellate proceedings — delivering a decisive win for Edwards Lifesciences and its co-defendant Edwards Lifesciences, LLC.
At the center of the dispute was U.S. Patent No. US10226341B2, directed to an implant for heart valve technology. The Federal Circuit’s affirmance reinforces the PTAB’s authority over patentability determinations in high-stakes medtech sectors and sends a clear signal to patent holders pursuing Inter Partes Review (IPR) challenges in cardiovascular device innovation.
The Parties
⚖️ Plaintiff
Israeli-based medical device developer focused on minimally invasive transcatheter heart valve technologies. The company has built an IP portfolio targeting structural heart disease.
🛡️ Defendant
Industry leader in patient-focused innovations for structural heart disease and critical care monitoring, with a significant market position in transcatheter heart valves.
The Patent at Issue
This landmark case involved U.S. Patent No. US10226341B2, directed to an implant for heart valve technology. The patent covers structural and functional features of a heart valve implant, directed to innovations in transcatheter valve delivery and anchoring mechanisms.
- • US10226341B2 — Implantable heart valve devices (Application No. US15/197069)
The litigation centered on Edwards’ heart valve implant products — commercially significant devices in the transcatheter aortic valve replacement (TAVR) market, which represents a multi-billion dollar global segment. The commercial stakes amplify the strategic importance of the invalidity outcome.
Developing a new medical device?
Check if your technology might infringe existing patents before significant investment.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a clean affirmance of the PTAB’s decision, finding Cardiovalve’s additional arguments on appeal unpersuasive. The court’s order stated explicitly:
“We have considered Cardiovalve’s additional arguments and find them unpersuasive. For the foregoing reasons, we affirm the Board’s decision. AFFIRMED.”
The basis of termination was unpatentability — meaning the claims of US10226341B2 were found invalid through the PTAB process, and that finding was upheld on appeal. No damages were awarded, as the case resolved on a validity challenge rather than an infringement determination.
Key Legal Issues
The Federal Circuit’s characterization of Cardiovalve’s arguments as “unpersuasive” — without detailed rebuttal — signals that the Board’s factual findings and legal conclusions were well-supported, leaving no reversible error for the appellate court to address. This language reflects the substantial evidence standard applied to PTAB fact-finding on appeal, a deferential review that historically favors Board outcomes.
This case reinforces several critical doctrinal points:
- PTAB Deference: The Federal Circuit continues to apply substantial evidence deference to PTAB unpatentability findings, making it extremely difficult for patent holders to overturn adverse IPR outcomes on appeal without identifying clear legal error.
- Medtech Patent Vulnerability: Heart valve and structural cardiac device patents face heightened scrutiny given a rich prior art landscape stretching back decades. Patent applicants in this field must carefully differentiate claims from voluminous existing literature.
- Strategic Use of PTAB by Accused Infringers: Edwards’ successful defense through PTAB proceedings — eliminating the patent entirely rather than merely defending an infringement claim — illustrates the strategic value of IPR as an offensive-defensive tool for market leaders.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for medtech.
- View related patents in the cardiovascular technology space
- Analyze active companies in heart valve innovation
- Understand PTAB success rates in medtech IPRs
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device or technology.
- Input your device description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Structural heart devices & TAVR technology
Dense Prior Art
Voluminous existing literature in medtech
PTAB Deference
Favors Board outcomes on appeal
✅ Key Takeaways
Federal Circuit deference to PTAB findings under the substantial evidence standard creates a high bar for reversal on appeal — build the record at the Board level.
Search related PTAB decisions →Claim construction and prosecution history are critically examined in IPR; weak differentiation from prior art makes cancellation likely.
Explore claim analysis tools →Edwards’ use of specialized PTAB counsel (Knobbe Martens) underscores the importance of expert IPR counsel selection.
Analyze litigation counsel effectiveness →Frequently Asked Questions
The dispute centered on U.S. Patent No. US10226341B2 (Application No. US15/197069), covering an implant for heart valve technology.
The court affirmed the PTAB’s determination of unpatentability, finding Cardiovalve’s appellate arguments unpersuasive under the deferential substantial evidence standard applied to Board factual findings.
It reinforces PTAB’s effectiveness as a validity-challenge forum in medtech, encourages defendants to pursue IPR strategies early, and signals that heart valve patent claims must be tightly differentiated from the existing prior art landscape to survive challenge.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case No. 22-2230
- USPTO Patent US10226341B2
- United States Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office (USPTO)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.